Request Demo
Recent blog posts
Latest Hotspot
8 min read
CTR20262594 Ropivacaine Hydrochloride Analgesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262594 clinical trial report covering Ropivacaine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262583 AC-101 Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262583 clinical trial report covering AC-101, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262579 HY-0902 Hyperuricemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262579 clinical trial report covering HY-0902, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128053 Ecnoglutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
ChiCTR2600128053 clinical trial report covering Ecnoglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07699601 HL-1186 Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07699601 clinical trial report covering HL-1186, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07700108 Lidocaine Phobic Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07700108 clinical trial report covering Lidocaine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07699939 Serplulimab PD-L1 positive Gastroesophageal junction adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07699939 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2011260024 Vibegron Urinary Bladder, Overactive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
JPRN-jRCT2011260024 clinical trial report covering Vibegron, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07697586 Sacituzumab tirumotecan Locally Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07697586 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07698054 Etoposide Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07698054 clinical trial report covering Etoposide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07699471 Canvuparatide Hypoparathyroidism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07699471 clinical trial report covering Canvuparatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07700056 Remibrutinib Pruritus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07700056 clinical trial report covering Remibrutinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.